Inspira Technologies Oxy B.H.N. Ltd. Stock

Equities

IINN

IL0011715781

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 02:41:56 2024-04-24 pm EDT 5-day change 1st Jan Change
1.905 USD +2.42% Intraday chart for Inspira Technologies Oxy B.H.N. Ltd. +0.26% +79.72%
Sales 2022 - Sales 2023 - Capitalization 14.17M
Net income 2022 -10M Net income 2023 -11M EV / Sales 2022 -
Net cash position 2022 12.45M Net cash position 2023 6.48M EV / Sales 2023 -
P/E ratio 2022
-1.36 x
P/E ratio 2023
-1.14 x
Employees 40
Yield 2022 *
-
Yield 2023
-
Free-Float 90.53%
More Fundamentals * Assessed data
Dynamic Chart
Inspira Technologies OXY B.H.N. Ltd Signs Collaboration Term Sheet with the Beilinson Hospital in Israel for the Evaluation of Its Proprietary INSPIRA ART100 device in Organ Transplant Procedures CI
Inspira, Beilinson Hospital Collaborate on Organ Transplant Device Evaluation MT
Inspira?? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections CI
Inspira? Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA? ART100 Device for an Artificial Womb CI
Inspira Technologies Oxy B.H.N. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA? ART100, to Enter the Southeast Asia and South American Markets CI
Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator CI
Inspira Technologies Oxy B.H.N. Ltd. Plans to Report the Primary Results for A Core Blood Oxygenation Technology Within Days CI
Inspira Technologies Oxy B.H.N. Ltd. Announces Approval from the U.S. Food & Drug Administration for its INSPIRA ART100 in the First Half of 2024 CI
Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Sector Update: Health Care MT
Inspira Gets US Patent Approval for Orbiting Blood Oxygenation Delivery System; Shares Rise MT
Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System CI
More news
1 day+2.42%
1 week+0.26%
Current month+8.86%
1 month+2.42%
3 months+93.40%
6 months+54.88%
Current year+79.72%
More quotes
1 week
1.80
Extreme 1.8
1.97
1 month
1.64
Extreme 1.64
2.36
Current year
0.76
Extreme 0.7613
2.36
1 year
0.76
Extreme 0.7613
2.49
3 years
0.76
Extreme 0.7613
9.59
5 years
0.76
Extreme 0.7613
9.59
10 years
0.76
Extreme 0.7613
9.59
More quotes
Managers TitleAgeSince
Founder 50 17-06-30
Founder 47 17-06-30
Director of Finance/CFO - 21-01-31
Members of the board TitleAgeSince
Chairman 73 21-01-31
Director/Board Member 50 21-07-15
Founder 47 17-06-30
More insiders
Date Price Change Volume
24-04-24 1.905 +2.42% 108 200
24-04-23 1.86 -2.11% 48,038
24-04-22 1.9 +5.56% 61,778
24-04-19 1.8 -0.55% 91,469
24-04-18 1.81 -4.74% 96,120

Delayed Quote Nasdaq, April 24, 2024 at 02:02 pm EDT

More quotes
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.86 USD
Average target price
13 USD
Spread / Average Target
+598.92%
Consensus